Top Markets
#1 ONFA ONFA +225.76%
#2 Resolv wstUSR Resolv wstUSR +198.02%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +38.13%
#6 NKN NKN +36.26%
#7 StakeStone StakeStone +28.59%
#8 BLOCKv BLOCKv +26.08%
#9 KONET KONET +24.91%
#10 OpenVPP OpenVPP +22.33%
Coin of the day
ONFA ONFA
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Hisse Senetlerindeki Sıralama #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Hisse Fiyatı
$0.5275
Piyasa Değeri
$1.25M
Değişim (1 gün)
-3.56%
Değişim (1 yıl)
-83.77%
Ülke
US
Ticaret Ensysce Biosciences, Inc. (ENSC)

Kategori

Healthcare
Ensysce Biosciences, Inc. (ENSC) için gelir
Sep 2025 itibarıyla gelir TTM: $4.49M
Ensysce Biosciences, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $4.49M'dir. 2023 yılında şirketin geliri $2.23M önceki yıla göre azalma 2022 yılındaki $2.52M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Ensysce Biosciences, Inc. için 2017 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2026 (TTM) $4.49M -13.85%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 1,079,095.70%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 268,123.28%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 319,469.02%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 202,258.79%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 349,599.93%
AU